Catalyst Pharmaceuticals, Teva and Firdapse
We recently compiled a list of the 10 Firms Kick Off 2025 Trading in The Red. In this article, we are going to take a look at ...
Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...
Shares of Catalyst Pharmaceuticals (CPRX) have resumed trading and are higher after the company announced that the company and its licensor ...
Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here ...
Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.24 which represents a decrease of $-0.06 or -0.28% from the prior close of $21.3. The stock opened at $21.4 and ...
NYSE:TEVA opened at $22.62 on Friday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.39 and a ...
Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well ...
Two Israeli stocks have been included in the top picks 2025 lists of US analysts. Bank of America chose Teva Pharmaceutical ...
Technical analysis for Teva Pharmaceutical Industries Limited American Depositary Shares TEVA including support levels ...
Clinical trials are essential for the development of health care products, and it is increasingly recognized that there is a ...
TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor.
Global Spinal Cord Injury Therapeutics Market is estimated to valued US$ 7.4 billion in 2023 & expected to exhibit CAGR of 5.4% during forecast period 2023-2030 Mr. Shah Coherent Market Insights Pvt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback